Strengthening Evidence on Optimal Multidrug-resistant Tuberculosis Treatment Regimens

Active, not recruitingOBSERVATIONAL
Enrollment

800

Participants

Timeline

Start Date

September 22, 2020

Primary Completion Date

December 30, 2025

Study Completion Date

December 31, 2025

Conditions
Tuberculosis, Multidrug-ResistantHIV
Interventions
DRUG

Bdq, Lzd, Lfx, Dlm, Cfz (9-12 months)

Bdq, Lzd, Lfx, Dlm, Cfz for nine months, with extension to 12 months as needed

DRUG

Bdq, Lzd, Lfx, Cfz, Cs (9-12 months)

Bdq, Lzd, Lfx, Cfz, Cs for nine months, with extension to 12 months as needed

DRUG

Bdq, Lzd, Lfx, Z, Dlm (9-12 months)

Bdq, Lzd, Lfx, Z, Dlm for nine months, with extension to 12 months as needed

Trial Locations (3)

Unknown

Partners In Health, Kazakhstan, Almaty

Partners In Health, Lesotho, Maseru

Socios En Salud, Lima

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

collaborator

Partners in Health

OTHER

collaborator

Socios En Salud Sucursal, Peru

OTHER

lead

Harvard Medical School (HMS and HSDM)

OTHER